Want to see MRNA full AI Analyst Report?
MRNA Stock Chart & Stats
$53.72
-$4.21(-8.86%)
At close: 4:00 PM EST
$53.72
-$4.21(-8.86%)
Day’s Range― - ―
52-Week Range$22.28 - $85.60
Previous CloseN/A
Volume7.58M
Average Volume (3M)8.52M
Market Cap
$27.09B
Enterprise Value$23.91B
Total Cash (Recent Filing)$5.21B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Jul 31, 2026EPS Estimate
-2.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.15
Shares Outstanding396,786,250
10 Day Avg. Volume8,921,115
30 Day Avg. Volume8,522,257
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue10.75
Enterprise Value/Gross Profit-77.38
Enterprise Value/Ebitda-8.29
Forecast
1Y Price Target
$46.64Price Target Upside-13.18% Downside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-8.42
Revenue Forecast (FY)$2.09B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and substantial equity provide a durable liquidity and capital buffer that supports sustained R&D investment and operating flexibility. This financial strength lengthens runway versus peers and helps absorb shocks such as one-time legal costs while management executes portfolio growth.
Product Portfolio ExpansionMultiple approvals and an expanding respiratory franchise (including flu+COVID combo and RSV) materially diversify revenue beyond a single COVID product. Structural portfolio breadth reduces single-product concentration risk and improves medium-term market opportunity across immunization programs.
Cost DisciplineSustained, measurable cuts to adjusted cash costs signal operational leverage and better cash stewardship. If management maintains these savings, it lowers the break-even hurdle, extends cash runway and increases odds of return to positive cash generation as revenue from new products ramps.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flow indicates the business currently consumes cash to fund operations and R&D. Even with a strong balance sheet, continued cash burn raises funding and runway risk over the medium term if new product revenues or margins do not improve.
Large Litigation ChargeA near-term, material cash payment and GAAP charge materially raises cost of sales and compresses liquidity. The settlement also leaves contingent legal exposure and multi-year timing uncertainty, increasing balance-sheet and earnings volatility during the 2–6 month horizon.
Profitability PressureNegative gross margins and deeply negative operating results reflect a cost structure outpacing current revenues. Until unit economics normalize and margins recover, the company will struggle to convert revenue growth into sustainable profitability, eroding equity over time.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $22.28 and its highest was $85.60 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $27.09B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Jul 31, 2026 which is in 19 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on May 01, 2026. The company reported -$3.4 earnings per share for the quarter, beating the consensus estimate of -$4.446 by $1.046.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.03.
How many shares outstanding does Moderna have?
Moderna has 396,786,250 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$3.4 in its last earnings report, beating expectations of -$4.446. Following the earnings report the stock price went down -1.241%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$46.64 (-13.18% Downside)
$46.64 (-13.18% Downside)
Blogger Sentiment
Bullish
MRNA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 178.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $433.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 13.8%
Last 30 Days ▲ 13.8%
News Sentiment
Neutral
Bullish news 57%
Bearish news 43%
Bearish news 43%
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.15%
12-Months-Change
Fundamentals
Return on Equity
-36.73%
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly constructive commercial and scientific update: strong Q1 revenue growth (driven by international strategic partnerships), multiple regulatory approvals (including the first flu+COVID combo), meaningful cost reductions (adjusted cash cost down 26% YoY) and continued pipeline advancement across respiratory, oncology and rare diseases. Offsetting these positives were a large, near-term litigation settlement charge recognized in Q1 that materially increased cost of sales and GAAP loss, potential contingent legal exposure (up to $1.3B) with multi‑year timing uncertainty, and expected cash drawdown through 2026. On balance, the company demonstrated operational execution and long‑term value drivers while managing a significant one‑time legal headwind.View all MRNA earnings summariesMRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$46.64
▼(-13.18% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Ownership Overview
7.74% Insiders
28.21% Mutual Funds
0.11% Other Institutional Investors
40.40% Public Companies and Individual Investors